Treatment consisted of the following: CyP, 100 mg/kg intraperitoneally at day 2; anti-αβTCR, 100 μg/each intraperitoneally at day –3; anti-CD8, 100 μg/each intraperitoneally at day –3; anti-CD154, 500 μg/each at days 0 and 3; anti-B220, 10 mg/each (SAS precipitated), intraperitoneally at days –21, –19, –17, –10, and –3; anti-class I, 400 μg/each intraperitoneally at day –1; anti-class II, 400 μg/each intraperitoneally at days –21, –19, –17, –10, and –3; anti-NK1.1, 1 mg/each intraperitoneally at days –3 and –1; splenectomy, at day –3; CD45RB, 1 mg (unpurified) intraperitoneally at days 0 and 1; CVF, 60 U/kg intraperitoneally at day –1 and 20 U/kg intraperitoneally at days 0, 1, 2, 3, 4, and 7; CyA, 15 mg/kg per day intraperitoneally at days 0 to 7; fludarabine, 100 mg/kg per day intraperitoneally at days –5 to –3; MMF, 20 mg/kg per day intraperitoneally at days –1 to 14; rapamycin, 3 mg/kg per day intraperitoneally at days 0 to 7; BMCs, 80 × 10⁶ per day at days 0, 2, and 4; targeting B cells, CyP at days –30 and –15; IVIG, 1 mg/kg per day at days 1, 2, and 3; and subtractive immunization with 15 × 10⁶ donor splenocytes at day –7, followed by CyP at days –6 and –5. MFI is presented as mean ± SD